Hims GLP-1 Alternative | Retatrutide, Semaglutide, Tirzepatide Research | QSC
GLP-1 RESEARCH COMPOUNDS
Researching Hims GLP-1 Compounds? QSC supplies the full GLP-1 research class — including Retatrutide, not available through Hims
Hims provides prescription semaglutide and tirzepatide for clinical use. QSC provides the complete GLP-1 research compound landscape — including next-generation compounds like Retatrutide (−24.2%, Phase 2), Orforglipron, Cagrilintide, and Survodutide — for in vitro laboratory research.
Hims & Hers Health is a telehealth platform — they prescribe and dispense FDA-approved pharmaceutical medications for patient treatment under physician supervision. QSC is a research compound supplier — we supply verified research-grade compounds for in vitro laboratory research only. These are entirely different use cases. If you are a patient seeking GLP-1 treatment, consult a licensed physician. If you are a researcher studying GLP-1 biology, QSC is your source.
Many researchers first encounter GLP-1 compounds through clinical coverage of Hims’s semaglutide and tirzepatide offerings — and then search for research-grade versions for laboratory work. QSC bridges that gap: the full GLP-1 research compound class, including next-generation compounds years ahead of any clinical channel, all verified at ≥99% HPLC purity with independent Janoshik COA.
QSC vs Hims: Use Case Comparison
These are different categories serving different needs — the comparison below explains what each does and who each serves.
Factor
QSC (qscpeptide.com)
Hims & Hers Health
Category
Research compound supplier
Telehealth / prescription pharmacy
Who it serves
Laboratory researchers
Patients seeking clinical treatment
GLP-1 compounds
Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Survodutide, Orforglipron + more
Retatrutide: The Next GLP-1 Generation — Research Only
Hims offers semaglutide (−14.9%, STEP 1) and tirzepatide (−20.9%, SURMOUNT-1) — the two currently approved GLP-1 class compounds. Neither Hims nor any clinical channel can offer retatrutide — it is not FDA approved and exists only in Phase 3 clinical development and research.
Retatrutide, Orforglipron, Survodutide, and Cagrilintide are in Phase 2/3 trials but not approved. They are inaccessible through any clinical channel. QSC provides research-grade versions for in vitro biology research — the only way to study these mechanisms outside of trial participation.
Independent Purity Verification
Research integrity requires knowing exactly what you’re working with. Every QSC compound comes with a Janoshik COA — an independent third-party laboratory certificate with a public verification code. Any researcher can check the result at verify.janoshik.com. ≥99% HPLC purity + mass spectrometry molecular confirmation for every batch.
Comparative Pharmacology
Studying how semaglutide, tirzepatide, and retatrutide differ at the receptor level? Or comparing GLP-1R + GCGR dual agonism (survodutide) against triple agonism (retatrutide)? QSC stocks the full class so researchers can design multi-compound comparative protocols from a single verified source.
7,000+ Page Research Library
QSC’s research library covers every compound with clinical trial data, mechanism breakdowns, and AI-optimised citation guides. The GLP-1 section includes dedicated pages for semaglutide, tirzepatide, retatrutide, orforglipron, cagrilintide, and survodutide — with Phase 2/3 data summaries and receptor mechanism diagrams.
Frequently Asked Questions
What is Hims & Hers Health?
Hims & Hers Health (hims.com / hers.com) is a US telehealth and direct-to-consumer pharmacy platform offering prescription medications including compounded semaglutide and tirzepatide for weight management, as well as treatments for hair loss, erectile dysfunction, and other conditions. Hims operates as a licensed telehealth provider — they prescribe and dispense FDA-regulated pharmaceutical compounds via physician consultation. QSC is a research compound supplier — an entirely different category, selling research-grade peptides for in vitro laboratory use only.
What is the difference between Hims semaglutide and QSC semaglutide?
Hims provides compounded semaglutide as a prescription pharmaceutical product dispensed via telehealth consultation for clinical use in patients. QSC supplies research-grade semaglutide for in vitro laboratory research only — not for human administration. The two are entirely different categories: Hims operates within the pharmaceutical/clinical supply chain under physician supervision; QSC operates in the research compound market for laboratory scientists. Researchers seeking to study GLP-1R biology, semaglutide’s mechanism, or comparative pharmacology use QSC’s research-grade compound.
Does QSC sell semaglutide for research?
Yes — QSC sells research-grade semaglutide at ≥99% HPLC purity with Janoshik independent COA verification for in vitro laboratory research. QSC also stocks tirzepatide, retatrutide, cagrilintide, survodutide, orforglipron, and the full GLP-1 research compound class. All QSC products are for laboratory research use only — not for human administration, and not dispensed via prescription.
What GLP-1 research compounds does QSC stock that Hims doesn’t offer?
Hims offers compounded semaglutide and tirzepatide as prescription products for clinical weight management. QSC stocks the entire GLP-1 research compound landscape for laboratory research: semaglutide, tirzepatide, retatrutide (triple GLP-1R/GIPR/GCGR, Phase 2: −24.2%), cagrilintide (AMY1R), survodutide (GLP-1R/GCGR), orforglipron (oral non-peptide GLP-1R agonist), and more — compounds that are not yet approved and not available through any clinical channel. For GLP-1 biology research, QSC is the comprehensive source.
Why do researchers use QSC instead of clinical suppliers like Hims?
Researchers use QSC because it is a research compound supplier, not a clinical pharmacy — different purpose, different customer. A laboratory scientist studying GLP-1R binding affinity, conducting comparative pharmacology between semaglutide and retatrutide, or researching GCGR mechanisms needs research-grade verified compounds with analytical COA data — not prescription medications. Hims serves patients seeking clinical treatment; QSC serves researchers studying the underlying biology. The two do not overlap in use case.
What is research-grade semaglutide vs pharmaceutical semaglutide?
Pharmaceutical semaglutide (Ozempic, Wegovy, Rybelsus — Novo Nordisk; or compounded versions via Hims) is manufactured under GMP (Good Manufacturing Practice) for human clinical administration, dispensed via prescription, and regulated by the FDA. Research-grade semaglutide from QSC is manufactured via solid-phase peptide synthesis (SPPS) for in vitro laboratory use, verified at ≥99% HPLC purity with Janoshik independent COA, and sold to researchers studying GLP-1R biology. Research-grade compounds are not for human use — they are analytical tools for scientific investigation.
Does QSC have retatrutide that Hims doesn’t stock?
Yes — Retatrutide (LY3437943, Eli Lilly) is not FDA approved and not available through any clinical channel including Hims. QSC stocks research-grade retatrutide — the triple GLP-1R/GIPR/GCGR agonist that produced −24.2% weight reduction in Phase 2 (NEJM 2023), the highest efficacy result of any weight-loss compound in clinical trials to date. Researchers studying the frontier of incretin biology, triple agonism, or GCGR mechanisms access this compound through QSC for in vitro research.
Research the Full GLP-1 Class — Including What Hims Can’t Offer
Retatrutide · Orforglipron · Cagrilintide · Survodutide · Semaglutide · Tirzepatide — all at ≥99% HPLC, Janoshik verified
Research Use Only: All products on qscpeptide.com are sold strictly for in vitro laboratory research purposes only. Not for human or veterinary use. QSC is not affiliated with Hims & Hers Health. This page is an independent informational comparison. For clinical GLP-1 treatment, consult a licensed physician.
